ARGENX SE - ADR (ARGX)

US04016X1019 - ADR

477.84  +0.05 (+0.01%)

ARGENX SE - ADR

NASDAQ:ARGX (9/28/2023, 10:10:00 AM)

477.84

+0.05 (+0.01%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)07-27 2023-07-27/bmo
Earnings (Next)10-27 2023-10-27/bmo
Ins OwnersN/A
Inst Owners53.38%
Market Cap27.97B
Shares58.54M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80.87
IPO07-10 2014-07-10
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ARGX Daily chart

Company Profile

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 843 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Company Info

ARGENX SE - ADR

Laarderhoogtweg 25

Amsterdam NOORD-HOLLAND 4811 AH

P: 31763030.0

CEO: Tim Van Hauwermeiren

Employees: 843

Website: https://www.argenx.com/

ARGX News

News Imagea day ago - Investor's Business DailyBiohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%

The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.

News Imagea day ago - The Motley FoolWhy Immunovant Stock Is Bolting Higher Today

The company may have best-in-class autoimmune disease therapy under its roof.

News Imagea day ago - Investor's Business DailyImmunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.

News Image2 days ago - Seeking AlphaImmunovant drives OmniAb on IMVT-1402 data; argenx slips

OmniAb shares rise while argenx shares decline after Immunovant posts positive early-stage data for its autoimmune drug candidate, IMVT-1402. Read more here.

News Image2 days ago - Investor's Business DailyImmunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.

News Image7 days ago - argenx SEargenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

ARGX Twits

Here you can normally see the latest stock twits on ARGX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example